GlassScriptPhysician profile
Babatunde Ogundipe
NPI 1497911267
$37,113.99
in general payments reported to CMS, 2019-2025
25 companies · $4,108 in 2025
The $4,108 reported for 2025 was more than what 94% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $252 · 2021: $2,703 · 2022: $4,198 · 2023: $16K · 2024: $9,437 · 2025: $4,108.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $14K · Food and Beverage: $13K · Travel and Lodging: $2,080 · Consulting Fee: $838 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $13,807.00 |
| Food and Beverage | $13,138.34 |
| Travel and Lodging | $2,079.53 |
| Consulting Fee | $837.50 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $18,898.71 | 2021-2025 | Abilify Mycite, Rexulti, Abilify Maintena |
| Abbvie INC. | $3,224.47 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $2,982.43 | 2020-2025 | Caplyta |
| Lundbeck LLC | $1,772.02 | 2021-2025 | Rexulti, Abilify Maintena |
| Corium, LLC | $1,374.28 | 2022-2025 | Azstarys |
| Janssen Pharmaceuticals, INC | $1,244.97 | 2021-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Supernus Pharmaceuticals, INC. | $1,108.59 | 2022-2025 | Qelbree, Qelbree |
| Sunovion Pharmaceuticals INC. | $945.89 | 2021-2022 | |
| Alkermes, INC. | $934.24 | 2022-2025 | Lybalvi, Aristada |
| Axsome Therapeutics, INC. | $740.17 | 2023-2025 | Auvelity |
| Teva Pharmaceuticals USA, INC. | $727.73 | 2020-2025 | Austedo Xr |
| Neurocrine Biosciences, INC. | $720.73 | 2023-2025 | Ingrezza |
| Tris Pharma INC | $611.25 | 2024-2025 | Dyanavel Xr |
| E.R. Squibb & Sons, L.L.C. | $388.11 | 2024-2025 | Cobenfy |
| Idorsia Pharmaceuticals US INC | $330.51 | 2022-2024 | Quviviq |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $285.77 | 2022-2025 | Trintellix |
| Bausch Health US, LLC | $213.46 | 2025 | Aplenzin, Wellbutrin |
| Noven Therapeutics, LLC | $170.71 | 2025 | Xelstrym |
| Neos Therapeutics, LP | $144.78 | 2025 | Adzenys Xr-Odt, Exxua |
| Allergan, INC. | $94.67 | 2020 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $88.48 | 2025 | Rejoyn |
| Vanda Pharmaceuticals INC. | $49.64 | 2025 | Fanapt |
| Sumitomo Pharma America, INC. | $21.95 | 2023 | Latuda |
| Collegium Pharmaceutical, INC. | $20.36 | 2025 | Jornay Pm |
| Ironshore Pharmaceuticals INC. | $20.07 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Babatunde Ogundipe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.